NVAX:NASDAQ
Novavax Inc
$10.46
arrow_downward
-1.32%(-0.14) 1D
$10.49
arrow_upward
+0.29% (+0.030)bedtimeAfter hours
Closed: Oct 2, 4:00:00 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NVAX...
Open
$10.80
High
$10.86
Low
$10.33
Mkt. cap
1.73B
Avg. vol.
5.63M
Volume
4.03M
52-wk high
$11.97
52-wk low
$6.20
EPS
-$1.52
Beta
2.44
Shares outstanding
164.95M
No. of employees
749
Open
$10.80
High
$10.86
Low
$10.33
Mkt. cap
1.73B
Avg. vol.
5.63M
Volume
4.03M
52-wk high
$11.97
52-wk low
$6.20
EPS
-$1.52
Beta
2.44
Shares outstanding
164.95M
No. of employees
749
News stories
From web sources and news partners
News Corp
·
1 day ago
Novavax Inc. stock underperforms Friday when compared to competitors
Profile
Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company developed the Novavax COVID-19 vaccine, now commercialized by Sanofi. The company also develops vaccines for influenza, respiratory syncytial virus, avian flu, shingles, Clostridioides difficile, and malaria.
Novavax develops proprietary immune-stimulating saponin-based immunologic adjuvants at a wholly owned Swedish subsidiary, Novavax AB. One of these, Matrix-M, is used in the Novavax COVID-19 vaccine. Wikipedia
About Novavax Inc
CEOJohn C. Jacobs
Employees749
Founded1987
HeadquartersGaithersburg, Maryland, United States
SectorBiotechnology
Websitenovavax.com